Filing Analysis
Cibus, Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a general business update via an 8-K filing.
📋 Key Facts
- Reporting period: Three months ended June 30, 2026.
- Announcement date: August 13, 2026.
- The filing includes the results of operations and financial condition as per Item 2.02.
Cibus, Inc. appointed Craig Wichner as Chief Executive Officer effective June 8, 2026, replacing Peter Beetham, who returns to his role as President and COO. The transition includes significant changes to board composition and executive compensation.
🚩 Red Flags
- Multiple leadership changes occurring simultaneously (CEO appointment, Interim CEO departure, and two board resignations).
📋 Key Facts
- Craig Wichner appointed CEO on June 8, 2026, with a base salary of $650,000.
- Mr. Wichner received an RSU award and a stock option award, each with a grant date fair value of $1,100,000.
- Peter Beetham transitioned from Interim CEO back to President and COO; his base salary was reduced from $650,000 to $585,000.
- Both Mr. Wichner and Dr. Beetham resigned from the Board of Directors effective June 8, 2026.
- The authorized number of directors was reduced to seven to enhance board independence.
- Mr. Wichner is the Founder and Managing Partner of Farmland LP, managing over $350 million in assets.
Cibus, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Stockholders elected nine directors, approved executive compensation on an advisory basis, and ratified BDO USA, P.C. as the independent auditor for 2026.
📋 Key Facts
- Annual Meeting held on June 2, 2026.
- Quorum achieved with 53,072,072 shares present or represented by proxy (69.52% of outstanding Class A Common Stock).
- Nine directors were elected to the Board: Mark Finn, Peter Beetham, Kimberly A. Box, Jean-Pierre Lehmann, August Moretti, Gerhard Prante, Rory Riggs, Thomas Urban, and Craig Wichner.
- Executive compensation for Named Executive Officers was approved on an advisory basis.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Cibus, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a general business update. The filing serves as a formal vehicle to furnish the quarterly earnings press release to the SEC.
🚩 Red Flags
- The company is operating under an Interim CEO (Peter Beetham), which may indicate ongoing management instability or a prolonged executive search.
📋 Key Facts
- The report covers financial results for the three months ended March 31, 2026.
- The announcement was made on May 14, 2026.
- Peter Beetham is identified as the Interim Chief Executive Officer in the signature block.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
Cibus, Inc. appointed Thomas Urban to its Board of Directors on April 7, 2026. Mr. Urban is an agribusiness veteran with extensive leadership experience at CellFor, Inc. and Pioneer Hi-Bred International, as well as a background in M&A.
📋 Key Facts
- Thomas Urban was appointed to the Board of Directors effective April 7, 2026.
- Mr. Urban is the founder of Agribusiness Advisors and previously served as CEO of CellFor, Inc. from 2004 to 2012.
- Urban's compensation includes a $60,000 annual cash retainer and $90,000 in grant date value equity compensation.
- The filing notes that Peter Beetham is currently serving as the Interim Chief Executive Officer.
- Mr. Urban has no reported related-party transactions or material interests requiring disclosure under Item 404(a).
Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for a public offering of approximately 6.98 million shares of Class A common stock at $2.15 per share. The company expects to raise approximately $13.5 million in net proceeds, or up to $16.0 million if the underwriter's over-allotment option is exercised in full.
🚩 Red Flags
- The company is currently led by an Interim Chief Executive Officer, suggesting potential management instability.
- Significant equity dilution for existing shareholders resulting from the issuance of nearly 7 million new shares.
📋 Key Facts
- Offering of 6,976,744 shares of Class A common stock at a price of $2.15 per share.
- Underwriter BTIG, LLC granted a 30-day option to purchase up to 1,046,511 additional shares.
- Estimated net proceeds of $13.5 million after deducting a 7.0% underwriting discount and other expenses.
- Company, directors, and executive officers are subject to a 60-day lock-up agreement.
- The offering is being conducted under an existing shelf registration statement on Form S-3 (File No. 333-273062).
- The report was signed by Peter Beetham in his capacity as Interim Chief Executive Officer.
Cibus, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, along with a business update. The results were furnished via a press release and signed by the company's Interim CEO.
🚩 Red Flags
- The company is currently operating under an Interim CEO, which may indicate leadership instability or an ongoing executive search.
📋 Key Facts
- Reporting date: March 17, 2026
- Financial results cover the fourth quarter and fiscal year ended December 31, 2025
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
- Peter Beetham is identified as the Interim Chief Executive Officer
Cibus, Inc. has entered into an underwriting agreement for a public offering of 13,333,333 shares of Class A common stock at $1.50 per share. The offering is expected to raise approximately $17.8 million in net proceeds.
🚩 Red Flags
- Significant dilution: The issuance of over 13 million shares at $1.50 represents a substantial increase in share count for a micro-cap company.
- Low share price: Pricing at $1.50 is often indicative of companies needing immediate liquidity to fund operations.
📋 Key Facts
- Offering size: 13,333,333 shares of Class A Common Stock.
- Offering price: $1.50 per share.
- Underwriter: BTIG, LLC (sole underwriter).
- Insider participation: Board members will purchase 1,000,000 shares at the offering price.
- Over-allotment option: Underwriter has a 30-day option to purchase up to 1,999,999 additional shares.
- Estimated net proceeds: Approximately $17.8 million (or $20.5 million if the over-allotment is fully exercised).
- Lock-up period: Company, directors, and executive officers are prohibited from selling or transferring common stock for 60 days following the agreement date.
- Underwriting discount: 6.25% of gross proceeds.
Cibus, Inc. is updating disclosures in connection with an announced underwritten offering. The company is undergoing significant restructuring to preserve capital, including a recent workforce reduction and streamlining of operations to focus on its Rice herbicide tolerance traits.
🚩 Red Flags
- Underwritten offering indicates immediate need for capital, likely dilutive to existing shareholders.
- Recent workforce reduction (34 employees) and restructuring suggest cost-cutting measures to preserve cash.
- Heavy reliance on future royalty estimates from uncommercialized traits (Rice HT).
📋 Key Facts
- Company is conducting an underwritten offering (details not fully disclosed in the snippet).
- Implemented a reduction in workforce of approximately 34 full-time employees as of Dec 31, 2025.
- Anticipates annual net cash usage to be $30.0 million or less during 2026 due to streamlining.
- Primary focus is on Rice herbicide tolerance traits with potential royalties >$200M in US/Latin America and up to $150M-240M in Asia.
- Rice HT trait commercial launch targeted for 2027-2028.
Cibus, Inc. announced the repurchase of 60,088 shares of Class A common stock from an employee, Anthony Moran, on December 31, 2025.
🚩 Red Flags
- Related-party transaction involving an employee
📋 Key Facts
- Repurchase date: December 31, 2025
- Number of shares purchased: 60,088 shares of Class A common stock
- Purchase price per share: $0.0001
- Counterparty: Anthony Moran (Company employee)
- The transaction was approved by the Company's Board of Directors.
Cibus, Inc. announced its financial results for the third quarter ended September 30, 2025, and provided a year-to-date business update via an 8-K filing.
📋 Key Facts
- Reporting period: Three months ended September 30, 2025
- Report date: November 13, 2025
- The company provided a year-to-date business update alongside quarterly results
- Interim CEO Peter Beetham signed the report
Cibus, Inc. announced the appointment of Craig Wichner to its Board of Directors and his assignment to the standing Strategy Committee, effective November 5, 2025.
📋 Key Facts
- Craig Wichner appointed to the Board of Directors effective Nov 5, 2025.
- Wichner will serve on the Board's standing Strategy Committee.
- Wichner is the Founder and Managing Partner of Farmland LP ($350M+ AUM).
- Annual cash retainer: $60,000 (payable semi-annually).
- Annual equity compensation: $90,000 grant date value under the 2017 Omnibus Incentive Plan.
- Wichner has no material interest in transactions required to be reported under Item 404(a).
Cibus, Inc. has appointed Cornelis (Carlo) Broos as the new Chief Financial Officer, effective September 18, 2025. Mr. Broos has served as the company's Interim CFO since October 2024 and is transitioning from his role as Senior Vice President of Finance.
🚩 Red Flags
- None identified. This is a transition from an interim role to a permanent role by an internal candidate.
📋 Key Facts
- Cornelis (Carlo) Broos appointed as Chief Financial Officer effective September 18, 2025.
- Mr. Broos has served as Interim CFO since October 1, 2024.
- Initial base salary established at €440,000.
- Employment is 'at-will' with severance benefits including 18 months of salary for termination without cause or for good reason.
- Change in Control provisions include up to 24 months of salary and full vesting of equity.
Cibus, Inc. announced the appointment of Kimberly A. Box to its Board of Directors, effective September 11, 2025. Notably, Ms. Box will serve on a special committee tasked with evaluating strategic alternatives to maximize shareholder value.
🚩 Red Flags
- The formation/assignment of a director to a special committee evaluating 'strategic alternatives' is often a precursor to M&A activity, sale of the company, or restructuring.
📋 Key Facts
- Kimberly A. Box appointed to the Board effective September 11, 2025.
- Ms. Box will serve on the Compensation Committee, Nominating and Corporate Governance Committee, and a special committee.
- The special committee is specifically tasked with evaluating 'strategic alternatives to maximize shareholder value'.
- Annual cash retainer for Ms. Box is $60,000, payable semi-annually.
- Equity compensation grant date value of $90,000 subject to board approval.
Cibus, Inc. announced its financial results for the second quarter ended June 30, 2025, and provided a year-to-date business update via an 8-K filing.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Three months ended June 30, 2025
- The company provided a year-to-date business update alongside the quarterly results.
- Interim CEO Peter Beetham signed the filing.
Cibus, Inc. announced a reduction in workforce involving approximately 34 full-time employees as part of a strategic shift to prioritize near-term commercial opportunities and streamline business focus. The company expects to incur $0.5 million in one-time severance and vacation charges in Q3 2025.
🚩 Red Flags
- Cost-cutting measures often indicate liquidity or cash burn concerns in micro-cap companies.
- Strategic shift toward 'currently funded' opportunities suggests limited runway for long-term R&D projects.
📋 Key Facts
- Reduction in workforce involves approximately 34 full-time employees.
- The reduction is intended to implement a streamlined business focus prioritizing currently funded commercial opportunities.
- Estimated one-time charge of $0.5 million for accrued vacation and severance payments.
- One-time charges are expected to be recognized in the third quarter of 2025.
- Workforce reduction process is expected to be completed by December 31, 2025.
Cibus, Inc. entered into Securities Purchase Agreements to conduct an SEC-registered public offering of 15,714,285 shares of Class A Common Stock. The proceeds are intended for weed management trait development in Rice and general working capital.
🚩 Red Flags
- The company explicitly mentions pursuing 'longer term financing,' suggesting current liquidity needs may be significant.
- Significant dilution likely due to the issuance of over 15 million new shares.
📋 Key Facts
- Offering size: 15,714,285 shares of Class A Common Stock.
- The offering is being conducted on a 'best efforts' basis via a placement agency agreement with A.G.P./Alliance Global Partners.
- Placement agent fees: 7.0% for certain Purchasers and 2.0% for others; no fee paid for shares sold to the Board Chairman.
- Use of proceeds: Funding development of weed management traits in Rice, working capital, and general corporate purposes.
- Lock-up/Restriction: A 60-day period following closing during which the Company and executive officers/directors are restricted from disposing of or hedging shares.
Cibus, Inc. announced a strategic realignment to streamline operations and preserve capital, focusing exclusively on its priority Rice traits (HT1 and HT3) and partner-funded sustainable ingredient programs. The company is implementing cost-reduction measures, including workforce reductions and facility rationalization, to reduce annual net cash burn to approximately $30 million by 2026.
🚩 Red Flags
- Significant restructuring involving 'rationalizing human capital resources' (layoffs).
- Explicit mention of the need for 'additional near-term funding to finance its activities' and challenges in obtaining capital.
- Concentration of remaining resources into a single crop (Rice) due to capital constraints.
- Risk that cost reduction targets may not be achieved in a timely manner or at all.
📋 Key Facts
- Strategic pivot to focus on weed management traits HT1 and HT3 in Rice and partner-funded biofragrance/sustainable ingredient programs.
- Targeting a reduction in annual net cash burn to ~$30.0 million by 2026 through cost-reduction actions.
- Cost reductions include rationalizing human capital resources (layoffs) and non-core facilities.
- Rice commercial launch targets: Latin America (2027–2028), US Mid-South (2028), India/Asia (2030).
- Regulatory milestones noted: USDA-APHIS 'not regulated' designation for Canola traits and Ecuador regulatory approval for Rice traits.
- The filing is an update to business disclosures in connection with a public offering announced on the same date.
Cibus, Inc. announced that stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the annual meeting held on May 22, 2025.
📋 Key Facts
- Stockholders approved the 2025 ESPP at the Annual Meeting on May 22, 2025.
- The plan includes an initial reservation of 326,384 shares of Class A common stock.
- The plan is subject to annual increases as described in the proxy statement.
Cibus, Inc. held its 2025 Annual Meeting of Stockholders on May 22, 2025, where shareholders approved several significant items including director elections and the repricing of warrants for an insider.
🚩 Red Flags
- Related-party transaction: Approval of warrant repricing for insider Rory Riggs.
- Potential Dilution: Approval of issuance of up to 9,040,000 shares via warrants and potential change of control provisions.
📋 Key Facts
- Annual Meeting held on May 22, 2025; quorum was approximately 64.94% (22,447,245 shares).
- Seven directors were elected: Rory Riggs, Peter Beetham, Mark Finn, Jean-Pierre Lehmann, August Moretti, Gerhard Prante, and Keith Walker.
- Shareholders approved the ratification of BDO USA, P.C. as independent auditors for FY 2025.
- Approval granted for issuance of up to 9,040,000 shares upon exercise of warrants from January 21, 2025 agreements.
- Shareholders approved the repricing of certain existing warrants held by Rory Riggs (Nasdaq Rule 5635(c)).
- Shareholders approved issuance of shares related to potential 'change of control' warrants held by Rory Riggs (Nasdaq Rule 5635(b)).
Cibus, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025, and provided a year-to-date business update.
🚩 Red Flags
- Use of an 'Interim' Chief Executive Officer suggests recent leadership instability or transition
📋 Key Facts
- Reporting period: Three months ended March 31, 2025
- Filing date: May 8, 2025
- The filing includes results of operations and financial condition updates
- Interim CEO Peter Beetham signed the report
This is an amendment to a previous 8-K filing regarding the appointment of Dr. Peter Beetham as Interim CEO. The amendment specifically discloses the approved base salary for his interim role.
🚩 Red Flags
- Interim CEO appointment often signals leadership instability or a transition period within the company.
📋 Key Facts
- Dr. Peter Beetham appointed as Interim Chief Executive Officer effective February 24, 2025.
- Board and Compensation Committee approved a 2025 base salary of $650,000 for Dr. Beetham on March 24, 2025.
- The filing is an Amendment (8-K/A) to the original report filed on February 28, 2025.
Cibus, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of earnings and includes a press release as Exhibit 99.1.
📋 Key Facts
- Reporting period: Fiscal year ended December 31, 2024.
- Announcement date: March 20, 2025.
- The filing contains results of operations and financial condition under Item 2.02.
Cibus, Inc. announced the resignation of CEO Rory Riggs on February 24, 2025. The company has appointed President and COO Peter Beetham as Interim CEO while a search for a permanent successor is conducted.
🚩 Red Flags
- Sudden departure of a Chief Executive Officer can create leadership uncertainty during critical growth phases.
📋 Key Facts
- Rory Riggs resigned as Chief Executive Officer effective February 24, 2025.
- Rory Riggs will continue to serve as a director and Chairman of the Board.
- Peter Beetham (President and COO) appointed as Interim CEO.
- The Board of Directors is initiating a search for a permanent CEO.
Cibus, Inc. entered into multiple securities purchase agreements for a registered direct offering of common stock and warrants, involving both outside investors and the company's CEO, Rory Riggs. The deal includes significant warrant amendments that drastically reduce exercise prices for existing investor warrants.
🚩 Red Flags
- Related-party transaction: The CEO (Rory Riggs) is participating in the securities offering as a purchaser.
- Significant dilution: Large issuance of common stock and warrants, including pre-funded warrants which are immediately exercisable at $0.0001.
- Warrant recapitalization: Drastic reduction of existing warrant exercise prices from ~$10 to $2.50 is highly dilutive to current shareholders.
📋 Key Facts
- Offering includes 4,340,000 shares of Class A Common Stock at $2.50 per share (including one common warrant each).
- Offering includes 4,700,000 pre-funded warrants at $2.4999 per unit.
- CEO Rory Riggs is a participant in the offering as a 'Purchaser'.
- Existing investor warrants are being amended to reduce exercise prices from $10.00/$10.07 down to $2.50.
- Placement agent (A.G.P.) to receive 7.0% fee on most proceeds and 2.0% on others.
- The offering is being conducted via a registered direct offering under an existing S-3 registration statement.
Cibus, Inc. announced a compensation adjustment for Mr. Carlo Broos, specifically the approval of a new 2025 base salary by the Compensation Committee.
📋 Key Facts
- The Compensation Committee approved a 2025 base salary for Mr. Carlo Broos.
- The new base salary is $320,000.
- The compensation change is effective as of December 3, 2024.
Cibus, Inc. announced the appointment of August Moretti to its Board of Directors and Audit Committee, effective November 18, 2024.
📋 Key Facts
- August Moretti appointed to the Board of Directors effective Nov 18, 2024.
- Mr. Moretti will also serve as a member of the Board's Audit Committee.
- Moretti brings extensive CFO experience from companies including 4D Molecular Therapeutics and Assertio Therapeutics.
- The appointment includes a standard indemnification agreement for directors.
Cibus, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024, and provided a year-to-date business update.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Three months ended September 30, 2024
- The filing includes results of operations and financial condition updates via Exhibit 99.1.
Cibus, Inc. filed an 8-K to provide an updated corporate presentation under Regulation FD disclosure. The filing does not contain material financial changes or structural shifts.
📋 Key Facts
- The company provided an updated corporate presentation (Exhibit 99.1) as of October 2024.
- The information is being released to comply with Regulation FD requirements for discussions with securityholders and other persons.
- Filed on October 29, 2024, by CEO Rory Riggs.
Cibus, Inc. has announced a strategic realignment involving an immediate reduction in workforce of approximately 26 employees and additional cost-cutting measures to preserve capital.
🚩 Red Flags
- Implicit liquidity concerns: The company explicitly mentions 'the need for additional near-term funding to finance its activities' and challenges in obtaining capital as risk factors.
- Strategic realignment/Restructuring: Often indicates a pivot or necessity due to cash burn management.
📋 Key Facts
- Immediate reduction in workforce of approximately 26 full-time employees.
- Estimated one-time costs of $0.35 million in Q4 2024 related to severance and accrued vacation.
- Initiated additional cost reductions including reducing expenditures for consultants/third-party providers and streamlining rent/facility expenses.
- Non-renewal of the lease for the Oberlin facility upon expiration in August 2025.
Cibus, Inc. has formally appointed Cornelis (Carlo) Broos as Interim Chief Financial Officer, effective October 1, 2024. This follows the previously announced departure of Wade King from the CFO role.
🚩 Red Flags
- Succession risk: The company is currently operating with an 'Interim' CFO, indicating a leadership gap in the finance department.
📋 Key Facts
- Cornelis (Carlo) Broos appointed as Interim CFO effective October 1, 2024.
- Mr. Broos is a long-tenured employee, having joined the company in 2011 and serving as SVP of Finance since 2024.
- Outgoing CFO Wade King will remain employed by the Company in a non-executive role during his leave of absence.
- No new compensatory arrangements were entered into for this interim appointment.
Cibus, Inc. announced that underwriters have partially exercised an option to purchase 289,953 additional shares of Class A common stock as part of a recent public offering. This follows the company's underwritten offering of 3,000,000 shares at $4.00 per share.
🚩 Red Flags
- Dilution: The issuance of additional shares via the underwriter option increases the total share count, potentially diluting existing shareholders.
📋 Key Facts
- Underwriters partially exercised an option to purchase 289,953 additional shares (Option Shares).
- The exercise price for the Option Shares is $4.00 per share.
- The original offering consisted of 3,000,000 shares of Class A common stock.
- The transaction was conducted pursuant to a shelf registration statement on Form S-3 (Registration No. 333-273062).
- Notification of partial exercise occurred on September 20, 2024.
Cibus, Inc. entered into an underwriting agreement to conduct a public offering of 3,000,000 shares of Class A common stock at $4.00 per share. The offering is expected to close on September 19, 2024, providing the company with approximately $11.2 million in net proceeds.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of new equity.
- Potential liquidity need indicated by the scale of the offering relative to typical micro-cap cash positions.
📋 Key Facts
- Offering size: 3,000,000 shares of Class A common stock.
- Offering price: $4.00 per share.
- Expected net proceeds: Approximately $11.2 million (potentially $12.8 million if the over-allotment option is exercised).
- Underwriters: Roth Capital Partners and A.G.P./Alliance Global Partners acting as representatives.
- Over-allotment option: Representatives have a 45-day option to purchase up to 450,000 additional shares.
- Lock-up period: Company and directors/officers are subject to a 30-day lock-up on selling common stock following the offering closing.
Cibus, Inc. provided supplemental disclosures in connection with an announced underwritten offering. The filing includes updates on the company's gene-editing technology platform (RTDS), strategic realignment efforts to preserve capital, and detailed market opportunity assessments for its trait pipeline.
🚩 Red Flags
- Explicit mention of 'continuing capital resource constraints'.
- Ongoing cost reduction initiatives including prioritization of near-term payment obligations.
- The filing is a supplement to an underwritten offering, indicating immediate need for liquidity/capital raising.
📋 Key Facts
- Company is conducting an underwritten offering (details of which are in a separate related filing).
- Strategic realignment initiated in October 2023 focuses on advancing late-stage activities: Pod Shatter Reduction (PSR), HT1, and HT3 traits.
- The company is implementing cost reduction initiatives to preserve capital, including reducing CapEx and streamlining independent contractor use.
- Current pipeline includes six productivity traits; three are 'developed' and in pre-commercialization testing with partners.
- Technology platform: Rapid Trait Development System (RTDS) and the 'Trait Machine' process designed to accelerate trait development from 12-16 years down to 3-5 years.
Cibus, Inc. announced that CFO Wade King is stepping down to take an indefinite leave of absence for family reasons, effective September 30, 2024. Carlo Broos, the current SVP of Finance, will succeed him as Interim CFO on the same date.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (even if for family reasons) can create temporary leadership instability.
- The term 'indefinite leave' creates uncertainty regarding when a permanent replacement will be sought or if the role will remain vacant long-term.
📋 Key Facts
- Wade King (CFO) is taking an indefinite leave of absence for family reasons, effective September 30, 2024.
- Carlo Broos (SVP of Finance) appointed as Interim CFO, effective September 30, 2024.
- Mr. King intends to return in a newly established Chief Risk Officer role upon his return from leave.
- Interim CFO Carlo Broos has significant experience including roles at Syngenta and Deloitte.
Cibus, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notice that earnings data is being released via press release.
📋 Key Facts
- Reporting period: Three months ended June 30, 2024
- Report date: August 8, 2024
- The company announced its financial results for the quarter ending June 30, 2024.
- Financial results are contained in Exhibit 99.1 (Press Release).
Cibus, Inc. entered into Securities Purchase Agreements to conduct a registered direct offering of 1,298,040 shares of Class A Common Stock and an equal number of common warrants. The offering includes participation from CEO Rory Riggs at a slightly higher price per share than other investors.
🚩 Red Flags
- Related-party transaction: The CEO is a participant in the securities offering.
- Warrant redemption trigger: Includes an operational milestone (Soybean platform announcement) which may signal management's desire to clear the warrant overhang upon positive news.
📋 Key Facts
- Total shares offered: 1,298,040 shares of Class A Common Stock.
- Total warrants offered: 1,298,040 common warrants (1 warrant per share).
- Offering price for most investors: $10.00 per share + warrant.
- Offering price for CEO Rory Riggs: $10.20 per share + warrant.
- Warrant exercise price: $10.00 (standard) or $10.07 (for CEO).
- Warrants expire on June 13, 2029.
- Redemption clause: Company can redeem warrants if a Soybean platform is announced and stock hits $20.00 for 15 consecutive days.
- Placement Agent fee: 6.0% for certain investors; 3.0% for others; 0% for the CEO.
Cibus, Inc. held its 2024 Annual Meeting of Stockholders on May 30, 2024. The meeting resulted in the election of six directors and the ratification of BDO USA, P.C. as independent auditors.
📋 Key Facts
- Annual Meeting held on May 30, 2024.
- Quorum was established with 15,812,850 shares (approx. 63.85%) present or represented by proxy.
- Six directors elected: Rory Riggs, Peter Beetham, Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, and Keith Walker.
- Compensation of named executive officers was approved on an advisory basis.
- Appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending Dec 31, 2024, was ratified.
Cibus, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Three months ended March 31, 2024
- The company is an emerging growth company as defined by the SEC.
Cibus, Inc. filed this 8-K to provide unaudited pro forma combined statements of operations for the fiscal year ended December 31, 2023. This follows the company's business combination with Cibus Global, LLC completed in May 2023.
📋 Key Facts
- Filing date: March 21, 2024
- Purpose: Providing unaudited pro forma combined statement of operations for the year ended December 31, 2023 (Exhibit 99.1)
- Context: Relates to the business combination with Cibus Global, LLC completed on May 31, 2023
- Previous filings referenced: June 1, 2023 and June 29, 2023 (8-K/A)
Cibus, Inc. announced its full-year financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual earnings performance.
📋 Key Facts
- Financial results for the year ended December 31, 2023, were announced on March 21, 2024.
- The report includes an attached press release (Exhibit 99.1) detailing the operational and financial performance.
Cibus, Inc. announced significant non-cash impairment charges for the fiscal year ended December 31, 2023, totaling approximately $249.4 million. The impairments relate to goodwill and in-process R&D indefinite-lived intangible assets acquired during the Cibus Global, LLC merger.
🚩 Red Flags
- Massive non-cash impairment charge ($249.4M) significantly impacting the balance sheet.
- Impairment driven by a decline in the Company's stock price, indicating market skepticism of asset valuations.
- The scale of the write-down suggests the 2023 merger valuation may have been highly optimistic.
📋 Key Facts
- Estimated non-cash impairment charge for goodwill: $150.4 million.
- Estimated non-cash impairment charge for in-process R&D indefinite-lived intangible assets: $99.0 million.
- Total estimated non-cash impairment charge for FY2023: ~$249.4 million.
- Impairment triggered by qualitative factors including declining stock price and macroeconomic conditions.
- The charges relate to assets acquired in the 2023 merger with Cibus Global, LLC.
- Financial statements for Q4 and FY2023 are not yet completed; figures are preliminary and unaudited.
Cibus, Inc. announced a significant technological breakthrough in its gene-editing platform involving the successful regeneration of plants from single cells in a wheat cultivar. This development is intended to enable scalable trait prototyping for wheat, focusing on disease resistance and nitrogen use efficiency.
🚩 Red Flags
- Forward-looking statements include risks regarding the need for additional funding and potential depletion of capital resources sooner than expected.
📋 Key Facts
- Successfully regenerated plants from single cells in a wheat cultivar.
- The breakthrough enables a scalable gene editing process specifically for wheat.
- Company intends to focus initial development on disease resistance and nitrogen use efficiency traits.
- Announcement made via press release dated January 9, 2024.
Cibus, Inc. entered into an 'at-the-market' (ATM) sales agreement with Stifel, Nicolaus & Company for the potential sale of up to $80 million in Class A common stock. The company intends to use the proceeds for R&D, seed trait development, and working capital.
🚩 Red Flags
- Potential significant dilution to existing shareholders due to the $80M ATM offering capacity.
- The need for immediate working capital/R&D funding often suggests a high cash burn rate common in biotech/agtech micro-caps.
📋 Key Facts
- Entered into a Sales Agreement with Stifel, Nicolaus & Company on January 2, 2024.
- The offering size is up to $80,000,000 in Class A common stock.
- Stifel will receive a commission of up to 3.0% of gross proceeds.
- The sale will be conducted as an 'at the market' (ATM) offering under Rule 415(a)(4).
- Proceeds are earmarked for seed trait development, Trait Machine maintenance, R&D, and working capital.
- Termination of a previous Open Market Sales Agreement with Jefferies LLC.